Citi initiates coverage of Maze Therapeutics with Buy rating

(Updated - September 23, 2026 5:02 AM EDT)

Citi analyst Eric Joseph initiated coverage of Maze Therapeutics (NASDAQ: MAZE) with an Buy rating and a 12-month price target of $50.00

Joseph cited the company's lead program MZE829, describing it as exhibiting "a best-in-class oral APOL1 inhibitor profile for the treatment of AMKD," and noted that pipeline candidate MZE782 is a potential treatment for PKU.

You May Also Be Interested In

• Senior Iranian Official To Reuters: Tehran Is Reviewing U.S. Response To Its Proposal To End Hostilities
• Pepsico (PEP) PT Lowered to $161 at BNP Paribas Exane, 'Expect Renewed Calls for Greater Urgency in NA'
• Scotiabank Reiterates Sector Outperform Rating on Capstone Copper Corp (CS:CN) (CSFFF)